A Double-blind, Placebo Controlled First-in-human Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Ascending Intra-articular Doses of SAR446959, in Participants With Osteoarthritis of the Knee.

The article discusses a Phase 1 clinical trial, NCT06704932, evaluating the safety, tolerability, pharmacokinetics, and pharmacodynamics of SAR446959 in participants with knee osteoarthritis. The study involves single intra-articular doses of SAR446959 in male and female participants aged 45 to 65 over a 28-week period. The trial aims to assess adverse events, pharmacokinetic parameters, and the presence of anti-drug antibodies. The study is currently recruiting participants in Germany and is expected to be completed by December 2025. [Extracted from the article]